The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Rationale for why BRCA1/2 alterations might influence response to immunotherapy in colorectal cancer
Olatunji Alese, MD, Emory University, Atlanta, GA, outlines the biological rationale for why BRCA1/2 alterations might influence response to immunotherapy in colorectal cancer. Preclinical data demonstrates DNA repair abnormalities from BRCA1/BRCA2 alterations create immunogenicity and high neoantigen load due to genomic instability. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
